Viking Global Investors TRVI trades
Ole Andreas Halvorsen
Ole Andreas Halvorsen Trevi Therapeutics Inc stake
total: 682
Trades details
- Total transactions:
- 7
- New positions:
- 1
- Added:
- 1
- Reduced:
- 5
- Held for:
- 0 quarters
- Latest activity:
- 2026 Q3
According to 2026 Q3 report, Ole Andreas Halvorsen holds 1,031,644 Trevi Therapeutics Inc (TRVI) shares with a market value of roughly $14.77M accounting for 0.05% of the overall portfolio. Viking Global Investors first purchased TRVI in 2022 Q3, initially acquiring about 4.40M shares. Since the initial investment in Trevi Therapeutics Inc (TRVI), Viking Global Investors has made 6 more transactions.
When did Ole Andreas Halvorsen buy Trevi Therapeutics Inc (TRVI)?
Ole Andreas Halvorsen first invested in Trevi Therapeutics Inc (TRVI) in 2022 Q3 at the reported quarter-end price of $1.54 per share.
Ole Andreas Halvorsen's historical trades in Trevi Therapeutics Inc
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q3
|
0.05%
|
1,031,644
|
$14.32
|
$14,773,142
|
-33.21% (-513,000)
|
-0.02%
|
|
2026 Q2
|
0.08%
|
1,544,644
|
$18.65
|
$28,807,611
|
-51.71% (-1,654,000)
|
-0.09%
|
|
2025 Q4
|
0.11%
|
3,198,644
|
$12.52
|
$40,047,023
|
-37.63% (-1,930,231)
|
-0.06%
|
|
2025 Q3
|
0.12%
|
5,128,875
|
$9.15
|
$46,929,206
|
+232.40% (+3,585,875)
|
+0.09%
|
|
2025 Q2
|
0.02%
|
1,543,000
|
$5.47
|
$8,440,210
|
-52.20% (-1,684,792)
|
-0.03%
|
|
2025 Q1
|
0.06%
|
3,227,792
|
$6.29
|
$20,302,812
|
-26.64% (-1,172,208)
|
-0.02%
|
|
2022 Q3
|
0.03%
|
4,400,000
|
$1.54
|
$6,776,000
|
new
|
+0.03%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.